ALEXANDRIA, Va., Nov. 6 -- United States Patent no. 12,459,894, issued on Nov. 4, was assigned to Palatin Technologies Inc. (Cranbury, N.J.).
"Orally active melanocortin receptor-4 compounds" was invented by James Bullington (Hamilton Square, N.J.), Axel Metzger (Jackson, N.J.) and John H. Dodd (Spring Mills, Pa.).
According to the abstract* released by the U.S. Patent & Trademark Office: "A compound of the formulawhere R1, R2, R3, R4, R5, R6a, and R6b are as defined in the specification and claims, or an enantiomer, stereoisomer or diastereoisomer thereof, or a pharmaceutically acceptable salt thereof, and the use thereof in the treatment of diseases, disorders, syndromes and conditions responsive to modulation of a melanocortin receptor...